This release contains forward-looking information about ponsegromab, an investigational monoclonal antibody designed to treat cachexia, including its potential benefits and late-stage development ...
Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a pivotal programme in 2025.
Results that may be inaccessible to you are currently showing.